Cabot Corporation

NYSE:CBT

Chemicals - Specialty

Basic Materials
$74.03 +1.09%

+$0.96 today

Market cap
$3.80B
Beta
0.83
P/E (TTM)
16.3
EPS (TTM)
$5.48
Dividend yield
2.04%
52W Low $58.33High $90.08

Volume 0.53M

Average 0.43M

CBT Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Cabot CorporationNYSE: CBT

Depreciation & Amortization · Q3 FY2026 · quarter ended Jun 2026

Depreciation & amortization growth accelerates

Q3 FY2026 depreciation & amortization of $50M rose 28.2% year over year, ahead of the +19.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 2.0% from the prior quarter. Over 3 fiscal years it compounded at +1.8% a year.

Context

  • Depreciation & amortization amounted to 4.1% of revenue in FY2025, up 0.4 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +28.2% holds above the trailing-twelve-month pace of +19.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$50M+2.0% QoQ
Last fiscal yearSep 2025
$154M+2.0% YoY
LTMJun 2026
$180M+19.2% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+28.2%——
1 year+2.0%——
3-year CAGR+1.8%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
154M USD
Year-over-year change
+2.0%
4-year CAGR
-1.0%

Depreciation & Amortization vs competitors

How CBT compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +19.2% is the 5th highest of 11, against a peer median of +13.4%.
  • Depreciation & amortization amounts to 5.0% of revenue for CBT, versus a peer median of 5.3%.
CBT Competitors
Depreciation & Amortization for CBT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SSLSasol LimitedFY2026ZAR 13.32B ZAR-4.9%-8.5%5.0%
CECelanese CorporationLTM Jun 2026$842M USD+7.7%+18.0%8.7%
MEOHMethanex CorporationLTM Jun 2026$478.09M USD+20.1%+6.2%11.2%
KNFKnife River CorporationLTM Jun 2026$213.28M USD+34.0%+18.0%6.4%
AVNTAvient CorporationLTM Sep 2026$191M USD+3.7%+4.5%5.6%
CBTCabot CorporationLTM Jun 2026$180M USD+19.2%+1.8%5.0%
FULH.B. Fuller CompanyLTM Aug 2026$138.46M USD-22.6%+6.7%3.9%
PRMPerimeter Solutions, Inc.LTM Jun 2026$80.68M USD+19.1%+4.0%10.7%
SXTSensient Technologies CorporationLTM Jun 2026$62.19M USD+2.1%+5.2%3.7%
HWKNHawkins, Inc.LTM Sep 2026$55.23M USD+19.4%+24.2%4.8%
WDFCWD-40 CompanyLTM Aug 2026$10.37M USD+26.6%+8.4%1.5%
Peer median (excluding CBT) —+13.4%+6.4%5.3%

Competitors are the stored peer set for CBT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Net Income286M243M484M424M376M
Depreciation & Amortization160M146M144M151M154M
Deferred Income Tax9M(40M)(156M)(37M)32M
Stock-Based Compensation21M23M20M25M24M
Change in Working Capital(244M)(448M)100M70M49M
Accounts Receivables7M(287M)153M(26M)76M
Inventory(174M)(259M)96M41M47M
Accounts Payables167M115M(152M)42M(67M)
Other Working Capital(244M)(17M)3M13M(7M)
Other Non-Cash Items25M176M3M59M30M
Operating Cash Flow257M100M595M692M665M
Capital Expenditures(195M)(211M)(244M)(241M)(274M)
Acquisitions (Net)(92M)70M6M00
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities101M23M24M6M(24M)
Investing Cash Flow(186M)(118M)(214M)(235M)(298M)
Debt Repayment36M298M(179M)(143M)(23M)
Common Stock Issued6M6M4M20M8M
Common Stock Repurchased(3M)(53M)(98M)(172M)(168M)
Dividends Paid(80M)(84M)(88M)(93M)(96M)
Other Financing Activities(19M)(22M)(42M)(27M)(57M)
Financing Cash Flow(60M)145M(403M)(415M)(336M)
Effect of Forex Changes8M(91M)54M(57M)4M
Net Change in Cash19M36M32M(15M)35M
Free Cash Flow62M(111M)351M451M391M

Cabot Corporation

NYSE:CBT

Intrinsic Alpha fair value

Locked

Current Price

$74.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.